Eli Lilly Aktie
WKN: 858560 / ISIN: US5324571083
|
04.11.2025 20:47:15
|
Eli Lilly, Novo Nordisk Stocks Rise on Reported $149 Obesity Drug Deal with White House
Eli Lilly and Company (NYSE:LLY) shares are in the spotlight following reports indicating the company is close to finalizing a White House agreement to provide its lowest-dose obesity medications at $149 per month, which could open the door to Medicare coverage and broader reimbursement options.What Happened: Eli Lilly and Novo Nordisk (NYSE:NVO) are reportedly getting ready to unveil new pricing agreements with the White House for their popular weight loss drugs. In exchange, the companies could see those treatments covered under Medicare, according to sources cited by Max Bayer at Endpoints News.The potential agreement, which may be revealed this week, involves the drugmakers providing their obesity drugs’ lowest dosage at $149 each month. This arrangement would unlock Medicare coverage, creating new reimbursement pathways for the ...Full story available on Benzinga.comWeiter zum vollständigen Artikel bei Benzinga
Der finanzen.at Ratgeber für Aktien!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Eli Lillymehr Nachrichten
Analysen zu Eli Lillymehr Analysen
| 20.12.24 | Eli Lilly Buy | Jefferies & Company Inc. | |
| 31.10.24 | Eli Lilly Buy | Jefferies & Company Inc. | |
| 13.02.24 | Eli Lilly Buy | Jefferies & Company Inc. |
Aktien in diesem Artikel
| Eli Lilly | 787,20 | -2,90% |
|
| Novo Nordisk | 39,18 | -2,31% |
|
| Novo Nordisk (spons. ADRs) | 39,15 | -2,61% |
|
| RISE Inc. | 33,00 | -2,94% |
|
Letzte Top-Ranking Nachrichten
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.